multiple myeloma

Celgene International’s Phase III study (MM-020/IFM 07-01) of oral Revlimid (Lenalidomide) in combination with low-dose dexamethasone (Rd) has met its primary endpoint of progression-free survival (PFS) in patients newly diagnosed with multiple myeloma.

According to the data, the combination demonstrated a statistically significant improvement in PFS against a comparator arm with a triplet regimen consisting of melphalan, prednisone and thalidomide (MPT).

A total of 1,623 patients ineligible for autologous stem cell transplantation have been randomised in the study with continuous oral lenalidomide plus low-dose dexamethasone until disease progression.

In addition, patients were randomised with lenalidomide plus low-dose dexamethasone for eighteen 28-day cycles; or melphalan, prednisone and thalidomide for up to twelve 42-day cycles (72 weeks).

Overall survival, response rate, quality of life and safety were the secondary endpoints of the Phase III randomised, international study, MM-020/IFM 07-01, also known as the ‘Front-Line Investigation of REVLIMID/Dexamethasone vs. Standard Thalidomide’ (FIRST) trial.

The company is currently evaluating the safety and efficacy in the treatment arms and expects to begin discussions with regulatory authorities based on the results to submit dossiers for registration in the US, Europe and other markets.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Revlimid is not approved for the treatment of patients with newly diagnosed multiple myeloma anywhere worldwide.


Image: Micrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Photo: courtesy of Nephron.